Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Neuroendocrine Tumor

Neuroendocrine Tumor

26

Pipeline Programs↗

42

Active Trials↗

17

Companies Involved↗

Neuroendocrine Tumor is an emerging landscape with 26 programs across 17 companies. 8 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

58/100

Pipeline Velocity

27/100

Mech. Concentration

11/100

Completion Rate

69/100

Attrition Rate

17/100

Pipeline

Programs by Phase

Preclinical3

Non-Drug Intervention Type

University Hospital, Toulouse

Belzutifan

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Zanzalintinib

Merck & Co.

Phase 18

Gallium Ga 68-DOTA-FAPI-04

University of Michigan Rogel Cancer Center

Gallium-68 DOTATATE

Stanford University

Gallium Ga 68-DOTATATE

Mayo Clinic

Fulvestrant

Fresenius Kabi USA, LLC

Peposertib

Merck & Co.

Phase 27

Alphamedix

Orano Med LLC

Pazopanib

Novartis

Triapine

Vion Pharmaceuticals

Terbium 161

Tata Memorial Hospital

Capecitabine

Engelhard Arzneimittel GmbH & Co.KG

Phase 38

Recombinant Human GM-CSF

Eastern Cooperative Oncology Group

Copper Cu 64 Dotatate

Vanderbilt-Ingram Cancer Center

Al18f-Octreotide

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Cabozantinib S-Malate

Exelixis

CAM2029

Camurus AB

Approved

No programs

Analysis

Modality Breakdown

75%

Small molecule

18 of 24 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 24 classified programs, each share of the total. Modality classified for 96% of 26 pipeline programs.

Analysis

Trial Status

117

clinical trials

Completed45 · 38%

Recruiting22 · 19%

Terminated15 · 13%

Active, not recruiting14 · 12%

Unknown status10 · 9%

Not yet recruiting5 · 4%

Other6 · 5%

Clinical Trials

Trial Activity

117 trials

NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus or Sunitinib or Cabozantinib in Metastatic/Unresectable Gastroenteropancreatic Neuroendocrine Tumours

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05773274·100 enrolled

A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors

Recruiting·EExelixis·Preclinical·NCT06943755·440 enrolled

A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors

Recruiting·National Cancer Institute (NCI)·Phase 1·NCT05687123·24 enrolled

Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT04665739·70 enrolled

Treatment Patterns and Outcomes in GEP NET: A Retrospective Observational Cohort Study (PRIME Initiative)

Recruiting· Novartis logo

Novartis·N/A·NCT07635316·4,023 enrolled

UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2/3 Neuroendocrine Tumors

Recruiting·AAbramson Cancer Center at Penn Medicine·Phase 2·NCT04339036·70 enrolled

A Study of Second-Line Treatment Response and Resistance Mechanisms in Pancreatic Neuroendocrine Tumors With Liver Metastases Based on cfDNA and Single-Cell PBMC Multi-omics

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07835893·80 enrolled

Underwater Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Small Rectal Neuroendocrine Tumors: A Prospective, Multicenter, Non-inferiority Trial

Recruiting·NNanfang Hospital, Southern Medical University·Preclinical·NCT07759960·174 enrolled

An Exploratory Study of [68Ga]Ga-Fibroblast Activation Protein Inhibitor 4 ([68Ga]Ga-FAPI-04) in Patients With High-Grade Neuroendocrine Neoplasms

Recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT07132645·30 enrolled

Evaluation of the Inflammation-based Index as a Predictive Marker of Clinical and Radiological Response in Patients Treated With Lu-177 Oxodotreotide for Intestinal Neuroendocrine Tumour

Recruiting·IInstitut Claudius Regaud·Preclinical·NCT06876532·150 enrolled

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Recruiting·VVanderbilt-Ingram Cancer Center·Approved·NCT06016855·6 enrolled

Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor

Recruiting·—·Phase 2/3·NCT05749289·400 enrolled

A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)

Recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT06505395·90 enrolled

FTT PET/CT in Pancreatic Neuroendocrine Tumors

Recruiting·—·Phase 1·NCT07114939·12 enrolled

Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors

Recruiting·TTata Memorial Hospital·Phase 2·NCT07404176·20 enrolled

Page 1 of 8

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)